(Q38168858)

30 August 2017

title

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin (English)

1 reference

generalized anxiety disorder

30 August 2017

0 references

1 reference

Charlotte Both

1

1 reference

30 August 2017

Georg Kojda

series ordinal

2

1 reference

30 August 2017

Christian Lange-Asschenfeldt

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

22 November 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

29-38

1 reference

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Altered cerebral blood flow patterns associated with pathologic worry in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Salivary cortisol levels in persons with and without different anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Evidence-based pharmacological treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Off-label uses of trazodone: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Generalized anxiety disorder: acute and chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

New approaches to the pharmacological management of generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Cognitive theories of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Long-term efficacy of pregabalin in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Characterizing and understanding body weight patterns in patients treated with pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin abuse, dependence, and withdrawal: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Pregabalin abuse and dependence in Germany: results from a database query

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Anxiety disorders and drug dependence: evidence on sequence and specificity among adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Human and economic burden of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.853617

10.1586/14737175.2014.853617

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference